Downloading...
Download

LAES

BPTH could be in for a bull market in 2025!One new low cap stock pick with my research described below, please do your own research aswell and remember these are risky moves - thus small allocation. I will be back with many crypto charts for next year as well, don't worry! Bio-Path Holdings (BPTH) Overview: Bio-Path Holdings, Inc. is a biotechnology company focused on developing nucleic acid cancer drugs using its proprietary DNAbilize antisense RNAi nanoparticle technology. This technology allows for the development of drugs that can be administered through intravenous transfusion, targeting specific genes associated with cancer. Last week, Bio-Path Holdings announced preclinical results for their drug candidate BP1001-A. The study demonstrated that BP1001-A enhances insulin sensitivity, suggesting its potential as a treatment for obesity in patients with Type 2 diabetes. In 2025, Bio-Path Holdings plans to initiate a first-in-human Phase 1 clinical trial for BP1001-A, focusing on validating its safety, measuring pharmacokinetics, and establishing dosing for potential pivotal trials. This trial is aimed at further exploring BP1001-A's potential as a treatment for obesity and related metabolic diseases in patients with Type 2 diabetes. A successful trial would likely lead to a significant increase in Bio-Path Holdings' stock price. The news of positive clinical results would be seen as a validation of the drug's potential, attracting more investor interest and possibly leading to partnerships or buyouts from larger pharmaceutical companies. SPECULATION: Estimating the yearly revenue potential and a fair valuation for Bio-Path Holdings (BPTH) based on BP1001-A's market entry involves several speculative assumptions, as we lack specific data on market penetration, pricing, competition, and long-term efficacy. Here's a theoretical breakdown: Revenue Potential: Market Size and Share: Obesity and Type 2 Diabetes Market: The global market for treatments of obesity and Type 2 diabetes is substantial. For context, the global diabetes market alone was valued at approximately $51.1 billion in 2022, expected to reach $81.6 billion by 2030, growing at a CAGR of around 6.5% (). However, BP1001-A would be competing in a segment of this market focused on novel treatments or those with a unique mechanism like insulin sensitivity enhancement. Assumed Market Share: Assuming BP1001-A captures a niche segment, let's speculate it achieves a 1% to 5% market share due to its novel mode of action and targeting a specific subset of Type 2 diabetes patients with obesity. Pricing and Usage: Drug Pricing: New diabetes drugs, especially those with innovative mechanisms, can be priced high. For instance, if we assume a yearly cost per patient of $10,000 (considering the high cost of biologics and similar therapies), Patient Population: If we estimate that 1% of the diabetic population globally (approximately 537 million adults in 2021 according to IDF) could benefit from this drug, that's about 5.37 million patients. At 5% market share, this would mean 268,500 patients. Revenue Calculation: Annual Revenue: If 268,500 patients use BP1001-A at $10,000 per year, the potential annual revenue would be approximately $2.685 billion. For a 1% market share (53,700 patients), it would be around $537 million. Valuation: DCF Approach: A Discounted Cash Flow (DCF) analysis would be the traditional method to value BPTH if BP1001-A were to generate such revenues. Here's a simplified speculative approach: Cash Flow: Assuming 50% of revenue translates into gross profit (considering R&D, marketing, and other costs), a 1% market share would yield $268.5 million in gross profit, and 5% would yield $1.3425 billion. Discount Rate: Biotech companies often have high discount rates due to risk. Let's assume a 15% discount rate for this speculative valuation. Growth & Terminal Value: Assume growth stabilizes after initial high growth years, with a terminal growth rate of 2% post-patent exclusivity period (which might be around 20 years from patent to market). Valuation Calculation: With a 1% market share scenario: Present Value of Cash Flows for first 10 years (assuming rapid growth then stabilization): $268.5M * Annuity Factor at 15% = $1.4 billion (very roughly). Terminal Value (Gordon Growth Model) = $268.5M * (1+0.02)/(0.15-0.02) = $2.14 billion. Total Equity Value = PV of cash flows + Terminal Value = $3.54 billion. With a 5% market share scenario: Present Value of Cash Flows for first 10 years: $1.3425B * Annuity Factor at 15% = $7 billion (again, very roughly). Terminal Value = $1.3425B * (1+0.02)/(0.15-0.02) = $10.7 billion. Total Equity Value = $17.7 billion. Market Multiples: If we use industry multiples (PE ratios for biotech can be very high, especially for novel treatments), with a PE ratio of 20-30 for a company with significant growth potential, the valuation based on earnings from BP1001-A alone would range from: 1% Market Share: $5.37 billion (20 * $268.5M) to $8.055 billion (30 * $268.5M). 5% Market Share: $26.85 billion (20 * $1.3425B) to $40.275 billion (30 * $1.3425B). Fair Valuation: Given these speculative numbers, a fair valuation for BPTH based solely on BP1001-A's potential would be somewhere in the middle of these ranges, adjusted for the company's current financials, other pipeline drugs, and market conditions. Considering the above, a conservative estimate might place BPTH's valuation in the range of $3 billion to $10 billion, depending on market penetration optimism, with the understanding that this is highly speculative and subject to countless variables including regulatory approval, actual market acceptance, and competitive landscape. CONCLUSION & TA: This simply means, IF(!) this drug is succesfull the market cap of this company would significantly rise. Currently we're sitting at a 5.43 million market cap (at close, so lower now), thus its a 100 to 1000x potential or it drops to zero. Last note, price needs to stay above $1 to stay compliant with Nasdaq rules or else there could be an inverse stock split 2 to 1 for example or they face delisting by the end of Q3 2025. I'm not too worried because this is the same as SEALSQ faced before it 10x'd in the last few weeks. TA wise: we're retesting previous resistance and the bull market support band. Chart has been down only for years, capitulation after capitulation thus chance of a rebound should be there. I grabbed a small allocation to sit out for 2025, if the clinical trials are successful, we'll in for a big bull market. If not succesfull, we'll likely lose our money. A very decent risk / reward ratio of you invest an amount you can afford to lose and not more than 5% of your portfolio. This is one of my low cap stock picks, next to LAES (10x since entry) and MOBX (entry last week, flat pa for now). I will be scouting for more but for now, happy holidays!
BLong
by cryptobullethbtcxlm
$LAES to the MOON!!As quantum computers begin to enter the market such as Google with Willow, I am already in favor of the next generation of digital processors. Think about NASDAQ:NVDA and their $3 trillion dollar market cap. Loving this stock at $2 when I first heard about it and saw prices surge quickly over $9. Currently adding positions and keeping a close eye on previous ATH for this stock. Knowing with momentum and development prices will be over $100 within the next couple years. First target is $30.00, followed by $65, then $150... Happy Trading. May 2025 be a phenomenal year for us all. Clear 61.80 retracement touch with momentum and continuation for the next push.
NASDAQ:LAESLong
by awash22
3
SealSQ gearing up for a bull market!SealSQ is a Swiss quantum resistant semiconductor manufacturer and it will release its new chips soon. The company is well positioned for corporate and governmental use, especially for new applications for the growing IOT market. The company has about FWB:30M in cash and can survive on that for at least a few years. They launch a satellite with these new chips in collaboration with Wisekey and the Swiss UAV company Parrot. Together with a launch on Hedera Hashgraph for efficient decentralized accounting through Sealcoin - a project that fosters device to device and device to end user IOT transactions. The chart has been hammered down for about 1.5 years and currently is looking to form a double bottom from August to November 2024 lows. Seems to me, most sellers should be done by here, capitulation is for sure behind us. SealSQ has a big incentive to regain $1 before Q2 2025 to stay listed on the Nasdaq and together with a growth outlook, it has a good chance in doing so. Yet, this is a risky play and a very low market cap of around $15M, thus high volatility - either to the upside or downside. It's an all or nothing type of play and if your risk averse, this not for you. Please do your own due diligence first before you make any decisions. The long term breakout target is $35 but first we need to stay above $0.60 to regain a bullish trend. Furthermore $1 and $2.2 are points of resistance. If it breaks $2.2, it can fly and smart investors are keen on deep tech and IOT, so who knows where this may go... Last thing, is a pending breakout of small caps towards ATH, which could fuel a rally for stocks like these. At current prices, it was interesting enough for me to dabble some crypto profits into this stock and see where it goes! Reminder, that this is not financial advice - do your own research.
NASDAQ:LAESLong
by cryptobullethbtcxlm
3
SEALSQ LAES Double bottomSEALSQ looking good here with a local gap fill and a local double bottom with a bullish divergence. Price also direct went back above all time resistance. LAES is now really moving sideways and thus in accumilation. This is a good spot to get some exposure - with such a low market cap, this can go 100x and of couse the company can also fail and go to zero. Do your own research but good risk / reward for me here (just don't bet the fam) See my other idea linked below for more detailed info.
NASDAQ:LAESLong
by cryptobullethbtcxlm
MOBX resistance / support flip, target: +100% nextMobix Labs had volatile pa after earnings, an overreaction as revenue was up over 400% beating estimates. They're still at an operating loss, which is normal for a startup. Story is simple, they did multiple acquisitions this year: RaGE Systems: Revenue for 2024: Not specified. Acquisition Cost: Approximately $2 million in cash, $10 million in Mobix Labs stock, and possible earn-out payments up to $8 million over eight fiscal quarters. Description: Provides radio frequency joint design and manufacturing services. J-Mark Connectors Inc.: Revenue for 2024: Not specified. Acquisition Cost: Financial terms remain undisclosed. Description: Specializes in custom interconnect solutions for industries like aerospace, military, and defense. Spacecraft Components Corp.: Revenue for 2024: Not specified, but 2023 unaudited revenues were $18.1 million with forecasted growth for the next two years. Acquisition Cost: Between $18 million and $24 million, with consideration to be paid in a combination of cash and equity, subject to earnout provisions. Description: Manufactures mission-critical electronics for the aerospace, defense, and transportation sectors. Now especially Spacecraft Components Corp. is notably as they do 18.1 million in revenue and are worth roughly 22 million. Mobix Labs reported about 3 million in revenue yesterday. This means they will do 7x the revenue after the acquisition is completed in Q1 2025. Next to that they secured the following contracts in 2024 that are not part of the current revenue: In 2024, Mobix Labs, Inc. secured the following contracts: M-1 Abrams Tank Army Contract: for filtered connectors. Sole Source Supply Contract: with Gulfstream Aerospace Corp. for custom filtered connectors used in their business-jet aircraft. GE HealthCare and PerkinElmer Contract: for the sale of proprietary electromagnetic filtering products used in pharmaceutical diagnostics and digital imaging solutions. Tomahawk Missile System Contract: for filtered connector parts. Javelin Missile System Contract: for guidance system components. A 15-month Contract: to supply critical components for aerospace and defense applications, though specific details about the customer or components were not specified. EMI Interconnect Solutions: announced new filtered ARINC connectors and secured aerospace customers. These contracts span various sectors, focusing mainly on military, defense, aerospace, and medical applications. --- Looks to me this company is undervalued and has a lot of growth ahead in 2025... I added on the dip and any buy under $2 should be good long term. Short term pa looks like a support resistance flip and a next target of $3.52 - I also like that this stock isn't popular whatsoever, similar to LAES (SEALSQ) when I found it. A patient hold for me, DYOR, happy holidays!
NASDAQ:MOBXLong
by cryptobullethbtcxlm
SEALSQ (NASDAQ: $LAES) Poised to Continue the Bullish Trend SEALSQ ( NASDAQ:LAES ) has broken through the ceiling of a falling trend channel in the medium long term. This indicates a slower falling rate initially, or the start of a more horizontal development. NASDAQ:LAES is between support at dollar 1.06 and resistance at dollar 1.40. A definitive break through of one of these levels predicts the new direction. The volume balance is positive and strengthens the stock in the short term. The RSI curve shows a rising trend, which could be an early signal of the start of a rising trend for the price as well.
NASDAQ:LAESLong
by DEXWireNews
4